# ğŸ¯ FMEA & Quality Risk Management (QRM) - Complete Guide
## Pharmaceutical Quality Risk Management and FMEA Methodology

**Version:** 1.0 Final  
**Last Updated:** December 2025  
**Target Audience:** QA/QC, Manufacturing, MSAT, Validation Engineers, Regulatory Affairs  
**Regulatory Focus:** ICH Q9 (R1), FDA Guidance, EU GMP Annex 20

---

## Table of Contents

1. [Introduction to Quality Risk Management](#section-1)
2. [ICH Q9 Framework](#section-2)
3. [Risk Assessment Tools Overview](#section-3)
4. [FMEA Methodology - Complete Guide](#section-4)
5. [Process FMEA (PFMEA)](#section-5)
6. [Design FMEA (DFMEA)](#section-6)
7. [Risk Ranking and Prioritization](#section-7)
8. [Risk Control and Mitigation](#section-8)
9. [Other QRM Tools](#section-9)
10. [Practical Examples and Case Studies](#section-10)
11. [Templates and Checklists](#section-11)
12. [Integration with Quality Systems](#section-12)

---

<a name="section-1"></a>
## 1. Introduction to Quality Risk Management

### ğŸ¯ What is Quality Risk Management?

**Definition (ICH Q9):**
```
Quality Risk Management is a systematic process for the assessment,
control, communication, and review of risks to the quality of the
drug product across the product lifecycle.
```

**Simple Explanation:**
```
QRM = Identifying what could go wrong + How bad it would be + 
      How to prevent it + Making sure prevention works
```

---

### ğŸ“Š Why QRM Matters in Pharma

```mermaid
graph TB
    A[Quality Risk Management] --> B[Patient Safety]
    A --> C[Product Quality]
    A --> D[Regulatory Compliance]
    A --> E[Business Protection]
    
    B --> B1[Prevent harm]
    B --> B2[Ensure efficacy]
    
    C --> C1[Consistent product]
    C --> C2[Meet specifications]
    
    D --> D1[ICH Q9 requirement]
    D --> D2[FDA expectation]
    D --> D3[EU GMP Annex 20]
    
    E --> E1[Avoid recalls]
    E --> E2[Reduce waste]
    E --> E3[Protect reputation]
    
    style A fill:#E74C3C,color:#fff
    style B fill:#2ECC71,color:#000
```

---

### ğŸ”„ Risk Management Lifecycle

```mermaid
graph LR
    A[Risk Assessment] --> B[Risk Control]
    B --> C[Risk Communication]
    C --> D[Risk Review]
    D --> A
    
    A1[Identify<br/>Analyze<br/>Evaluate] --> A
    B1[Reduce<br/>Accept<br/>Control] --> B
    C1[Document<br/>Share<br/>Report] --> C
    D1[Monitor<br/>Update<br/>Improve] --> D
    
    style A fill:#3498DB,color:#fff
    style B fill:#F39C12,color:#fff
    style C fill:#9B59B6,color:#fff
    style D fill:#1ABC9C,color:#fff
```

---

### ğŸ“‹ When to Apply QRM

```yaml
Product Lifecycle Stages:

Development:
  âœ“ Formulation development
  âœ“ Process development
  âœ“ Scale-up studies
  âœ“ Clinical trial material manufacturing
  âœ“ Technology transfer
  
  Risk Focus: Design and process robustness

Commercial Manufacturing:
  âœ“ Routine production
  âœ“ Process changes
  âœ“ Equipment changes
  âœ“ Site changes
  âœ“ Supplier changes
  
  Risk Focus: Maintaining state of control

Specific Applications:
  âœ“ Change control
  âœ“ Deviation investigation
  âœ“ CAPA effectiveness
  âœ“ Out-of-specification (OOS) results
  âœ“ Validation activities
  âœ“ Supplier qualification
  âœ“ Cleaning validation
  âœ“ Computer system validation
  âœ“ Stability program design
  âœ“ Reprocessing/rework decisions
```

---

<a name="section-2"></a>
## 2. ICH Q9 Framework

### ğŸ“– ICH Q9 (R1) Principles

**Two Primary Principles:**

```yaml
Principle 1: Quality Risk Management Process
  "The evaluation of the risk to quality should be based on
   scientific knowledge, experience with the process, and
   ultimately link to the protection of the patient"

Principle 2: Level of Effort
  "The level of effort, formality, and documentation of the
   quality risk management process should be commensurate
   with the level of risk"
```

**Key Concept: Risk-Based Approach**
```
High Risk â†’ Extensive analysis, documentation, controls
Medium Risk â†’ Moderate analysis and controls
Low Risk â†’ Simplified analysis, basic controls

NOT one-size-fits-all!
```

---

### ğŸ” ICH Q9 Risk Management Process

```mermaid
stateDiagram-v2
    [*] --> Risk_Assessment
    
    Risk_Assessment --> Risk_Identification: Step 1
    Risk_Identification --> Risk_Analysis: Step 2
    Risk_Analysis --> Risk_Evaluation: Step 3
    
    Risk_Evaluation --> Risk_Control: If unacceptable
    Risk_Evaluation --> Risk_Communication: If acceptable
    
    Risk_Control --> Risk_Reduction: Option 1
    Risk_Control --> Risk_Acceptance: Option 2
    
    Risk_Reduction --> Risk_Review
    Risk_Acceptance --> Risk_Review
    
    Risk_Communication --> Risk_Review
    
    Risk_Review --> Risk_Assessment: Trigger event
    Risk_Review --> [*]: Maintained
    
    note right of Risk_Assessment
        Identify hazards
        Analyze risks
        Evaluate significance
    end note
    
    note right of Risk_Control
        Reduce to acceptable level
        Implement controls
        Verify effectiveness
    end note
```

---

### ğŸ“Š Risk Assessment Components

**Step 1: Risk Identification**
```yaml
Question: "What might go wrong?"

Activities:
  âœ“ Brainstorm potential failure modes
  âœ“ Review historical data (deviations, OOS, complaints)
  âœ“ Consider all process steps
  âœ“ Include equipment, materials, methods, environment
  âœ“ Think about "what if" scenarios

Output: List of potential hazards/failure modes

Example (Tablet Compression):
  - Wrong compression force
  - Tablet weight variation
  - Sticking/picking
  - Capping/lamination
  - Contamination
  - Equipment malfunction
```

---

**Step 2: Risk Analysis**
```yaml
Questions: 
  - "What is the likelihood of occurrence?"
  - "What is the severity of harm?"
  - "How easily can we detect it?"

Activities:
  âœ“ Estimate probability of occurrence
  âœ“ Estimate severity of consequences
  âœ“ Estimate detectability (for FMEA)
  âœ“ Calculate risk level
  âœ“ Qualitative or quantitative assessment

Output: Risk level for each hazard

Example (Wrong compression force):
  Probability: Medium (equipment malfunction possible)
  Severity: High (tablets fail hardness, dissolution)
  Detectability: Medium (in-process checks)
  Risk Level: Medium-High (requires attention)
```

---

**Step 3: Risk Evaluation**
```yaml
Question: "Is this risk acceptable?"

Activities:
  âœ“ Compare risk level to acceptance criteria
  âœ“ Prioritize risks
  âœ“ Determine if risk reduction needed
  âœ“ Consider regulatory expectations
  âœ“ Consider patient safety

Output: Decision (acceptable or needs control)

Acceptance Criteria Example:
  High Risk (RPN >200): NOT acceptable - immediate action
  Medium Risk (RPN 100-200): Review - controls needed
  Low Risk (RPN <100): Acceptable - monitor

Note: Criteria should be defined in advance
```

---

### ğŸ›¡ï¸ Risk Control Strategies

```yaml
Risk Reduction Options:

1. Eliminate the Hazard:
   Example: Remove a non-essential excipient that causes issues
   Best option if feasible

2. Reduce Probability:
   Example: Implement preventive maintenance to reduce equipment failure
   Controls: Automation, training, procedures, redundancy

3. Reduce Severity:
   Example: Add an in-process check to catch defects early
   Controls: Testing, inspection, containment

4. Improve Detection:
   Example: Install real-time monitoring equipment
   Controls: PAT, automated inspection, increased sampling

5. Accept the Risk:
   Example: Very low probability + low severity
   Condition: Justified and documented

Hierarchy of Controls (Best to Worst):
  1. Elimination
  2. Substitution
  3. Engineering controls
  4. Administrative controls
  5. Personal protective equipment (PPE)
```

---

<a name="section-3"></a>
## 3. Risk Assessment Tools Overview

### ğŸ”§ ICH Q9 Recognized Tools

```yaml
Tool: FMEA (Failure Mode and Effects Analysis)
  Best For: 
    - Process risk assessment
    - Design risk assessment
    - Detailed, systematic analysis
  Complexity: Medium-High
  Output: Risk Priority Number (RPN)
  Use Case: Manufacturing process, equipment design

Tool: FMECA (Failure Mode, Effects and Criticality Analysis)
  Best For:
    - Equipment criticality
    - System design
  Complexity: High
  Output: Criticality rating
  Use Case: Equipment qualification, system design

Tool: HACCP (Hazard Analysis and Critical Control Points)
  Best For:
    - Food safety
    - Contamination control
  Complexity: Medium
  Output: Critical Control Points (CCPs)
  Use Case: Sterile manufacturing, contamination control

Tool: Risk Ranking and Filtering
  Best For:
    - Quick assessment
    - Change control
    - Screening many risks
  Complexity: Low
  Output: Risk score (Low/Medium/High)
  Use Case: Change control, deviations

Tool: Fault Tree Analysis (FTA)
  Best For:
    - Root cause analysis
    - Complex systems
    - Tracing back from failure
  Complexity: High
  Output: Probability of top event
  Use Case: Investigations, system reliability

Tool: Ishikawa (Fishbone) Diagram
  Best For:
    - Root cause brainstorming
    - Visual cause-effect
  Complexity: Low
  Output: Cause categories
  Use Case: Deviation investigations

Tool: Risk Matrix
  Best For:
    - Simple risk rating
    - Quick decisions
  Complexity: Low
  Output: Risk level (grid)
  Use Case: Initial screening, change control
```

---

### ğŸ“Š Tool Selection Matrix

```yaml
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Tool            â”‚Complexityâ”‚ Time       â”‚ Best Application   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Risk Matrix     â”‚   Low    â”‚  < 1 hour  â”‚ Quick screening    â”‚
â”‚ Risk Ranking    â”‚   Low    â”‚  1-2 hours â”‚ Change control     â”‚
â”‚ Ishikawa        â”‚   Low    â”‚  1-2 hours â”‚ Root cause brainstormâ”‚
â”‚ FMEA            â”‚  Medium  â”‚  4-8 hours â”‚ Process analysis   â”‚
â”‚ HACCP           â”‚  Medium  â”‚  1-2 days  â”‚ Contamination      â”‚
â”‚ FTA             â”‚   High   â”‚  2-4 days  â”‚ Complex systems    â”‚
â”‚ FMECA           â”‚   High   â”‚  3-5 days  â”‚ Equipment criticalityâ”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Selection Criteria:

Use Risk Matrix when:
  âœ“ Quick decision needed
  âœ“ Change control
  âœ“ Initial screening
  âœ“ Limited information

Use FMEA when:
  âœ“ New process development
  âœ“ Detailed process understanding needed
  âœ“ Prioritization of many risks
  âœ“ Design or process optimization
  âœ“ Regulatory expectation (validation)

Use FTA when:
  âœ“ Investigating specific failure
  âœ“ Complex system with many contributors
  âœ“ Need to quantify probability
  âœ“ Compliance or safety critical
```

---

<a name="section-4"></a>
## 4. FMEA Methodology - Complete Guide

### ğŸ“– What is FMEA?

**FMEA = Failure Mode and Effects Analysis**

**Definition:**
```
A systematic, proactive method for identifying potential failure modes
in a product, process, or service, analyzing their effects, and
prioritizing actions to reduce or eliminate failures.
```

**Key Characteristics:**
- **Bottom-up approach**: Start with individual failure modes
- **Systematic**: Follows structured methodology
- **Preventive**: Identifies issues before they occur
- **Quantitative**: Uses numerical scoring (RPN)
- **Living document**: Updated throughout lifecycle

---

### ğŸ¯ FMEA Objectives

```yaml
Primary Objectives:

1. Identify Potential Failures:
   - What could go wrong?
   - Where in the process?
   - What are the failure modes?

2. Assess Impact:
   - How serious is the effect?
   - What is the consequence to patient/product?
   - Regulatory impact?

3. Prioritize Risks:
   - Which failures are most critical?
   - Where to focus improvement efforts?
   - Resource allocation

4. Implement Controls:
   - How to prevent failures?
   - How to detect failures early?
   - Verification of effectiveness

5. Document Knowledge:
   - Capture lessons learned
   - Support regulatory submissions
   - Training tool
```

---

### ğŸ“Š FMEA Structure

```yaml
FMEA Header Information:

Product/Process: _____________________
FMEA Number: _____________________
FMEA Date: _____________________
Revision: _____________________

Team Members:
  - Leader: _____________________
  - Process Engineer: _____________________
  - Quality Engineer: _____________________
  - Manufacturing Representative: _____________________
  - Subject Matter Expert: _____________________

Scope: _____________________

FMEA Table Columns:

Column 1: Process Step / Function
  Description: What is being analyzed?
  Example: "Tablet Compression"

Column 2: Potential Failure Mode
  Description: How could it fail?
  Example: "Incorrect tablet weight"

Column 3: Potential Effects of Failure
  Description: What happens if it fails?
  Example: "Dose variation, patient harm"

Column 4: Severity (S)
  Description: How serious is the effect?
  Scale: 1-10 (1=negligible, 10=catastrophic)
  Example: 8

Column 5: Potential Causes
  Description: Why might it fail?
  Example: "Hopper low level, worn tooling"

Column 6: Occurrence (O)
  Description: How likely is the cause?
  Scale: 1-10 (1=unlikely, 10=very likely)
  Example: 4

Column 7: Current Controls (Prevention)
  Description: How do we prevent it?
  Example: "Hopper level alarm, PM schedule"

Column 8: Current Controls (Detection)
  Description: How do we detect it?
  Example: "In-process weight checks every 15 min"

Column 9: Detection (D)
  Description: How likely to detect before customer?
  Scale: 1-10 (1=certain detection, 10=no detection)
  Example: 3

Column 10: Risk Priority Number (RPN)
  Calculation: RPN = S Ã— O Ã— D
  Example: 8 Ã— 4 Ã— 3 = 96

Column 11: Recommended Actions
  Description: What should we do?
  Example: "Install continuous weight monitoring"

Column 12: Responsibility
  Description: Who will do it?
  Example: "John Smith (Mfg Engineer)"

Column 13: Target Completion
  Description: When?
  Example: "Q2 2025"

Column 14: Actions Taken
  Description: What was actually done?
  Example: "Weight monitor installed, validated"

Column 15: Resulting S, O, D, RPN
  Description: New scores after actions
  Example: S=8, O=4, D=2, RPN=64
```

---

### ğŸ”¢ FMEA Scoring - Severity (S)

```yaml
Severity Scale (1-10):

Rating: 10 - Catastrophic
  Effect: Hazardous without warning
  Impact: Patient death or serious harm
  Regulatory: Recalls, warning letters
  Example: Wrong API in formulation

Rating: 9 - Very High
  Effect: Hazardous with warning
  Impact: Serious patient harm
  Regulatory: Regulatory action likely
  Example: Contamination with pathogen

Rating: 8 - High
  Effect: Product fails to meet critical requirements
  Impact: Efficacy compromised
  Regulatory: Batch rejection, investigation
  Example: Assay <80% of label claim

Rating: 7 - Moderate to High
  Effect: Product fails to meet important requirements
  Impact: Reduced efficacy
  Regulatory: Investigation required
  Example: Dissolution slightly out of spec

Rating: 6 - Moderate
  Effect: Product degraded but usable
  Impact: Minor efficacy reduction
  Regulatory: OOS investigation
  Example: Tablet appearance defect

Rating: 5 - Low to Moderate
  Effect: Functionality affected
  Impact: Customer complaint likely
  Regulatory: Documentation required
  Example: Slight weight variation (still within spec)

Rating: 4 - Low
  Effect: Minor defect
  Impact: Customer may notice
  Regulatory: Minor documentation
  Example: Cosmetic defect

Rating: 3 - Very Low
  Effect: Very minor defect
  Impact: Most customers won't notice
  Regulatory: None
  Example: Slight color variation (within limits)

Rating: 2 - Minor
  Effect: Barely noticeable defect
  Impact: Unlikely to be noticed
  Regulatory: None
  Example: Minor coating imperfection

Rating: 1 - None
  Effect: No effect
  Impact: None
  Regulatory: None
  Example: No failure

Key Principle:
  Severity is based on EFFECT, not probability
  Severity rating does NOT change unless design changes
```

---

### ğŸ”¢ FMEA Scoring - Occurrence (O)

```yaml
Occurrence Scale (1-10):

Rating: 10 - Almost Certain
  Probability: â‰¥ 1 in 2 (â‰¥50%)
  Frequency: Multiple times per batch
  Cpk: < 0.55
  Example: Known design weakness, happens frequently

Rating: 9 - Very High
  Probability: 1 in 3 (33%)
  Frequency: Once per batch
  Cpk: â‰¥ 0.55
  Example: Frequent equipment issues

Rating: 8 - High
  Probability: 1 in 8 (12.5%)
  Frequency: Once per few batches
  Cpk: â‰¥ 0.78
  Example: Recurring material variation

Rating: 7 - Moderate to High
  Probability: 1 in 20 (5%)
  Frequency: Once per month
  Cpk: â‰¥ 0.86
  Example: Occasional equipment failure

Rating: 6 - Moderate
  Probability: 1 in 80 (1.25%)
  Frequency: Once per quarter
  Cpk: â‰¥ 1.00
  Example: Periodic issue

Rating: 5 - Low to Moderate
  Probability: 1 in 400 (0.25%)
  Frequency: Once per year
  Cpk: â‰¥ 1.10
  Example: Rare occurrence

Rating: 4 - Low
  Probability: 1 in 2,000 (0.05%)
  Frequency: Once per 2-3 years
  Cpk: â‰¥ 1.20
  Example: Very rare

Rating: 3 - Very Low
  Probability: 1 in 15,000 (0.007%)
  Frequency: Once per 5 years
  Cpk: â‰¥ 1.30
  Example: Extremely rare

Rating: 2 - Remote
  Probability: 1 in 150,000 (0.0007%)
  Frequency: Once per 10+ years
  Cpk: â‰¥ 1.67
  Example: Nearly impossible

Rating: 1 - Nearly Impossible
  Probability: â‰¤ 1 in 1,500,000 (â‰¤0.00007%)
  Frequency: Never occurred
  Cpk: â‰¥ 2.00
  Example: Theoretical only

Guidance for Rating:
  - Use historical data when available
  - Consider similar processes/products
  - Conservative estimates appropriate
  - Update as more data becomes available
```

---

### ğŸ”¢ FMEA Scoring - Detection (D)

```yaml
Detection Scale (1-10):

Note: Lower score = Better detection capability

Rating: 1 - Almost Certain Detection
  Detection: Defect obvious, cannot reach customer
  Controls: Automated detection with 100% inspection
  Reliability: Error-proof design
  Example: Automated weight check, auto-reject OOS

Rating: 2 - Very High Detection
  Detection: Very likely to detect
  Controls: Multiple automated checks
  Reliability: >99.9% detection
  Example: Automated vision system + manual check

Rating: 3 - High Detection
  Detection: High probability of detection
  Controls: Automated detection
  Reliability: >99% detection
  Example: 100% automated inspection

Rating: 4 - Moderately High Detection
  Detection: Moderate-high probability
  Controls: Automated or extensive manual checks
  Reliability: >95% detection
  Example: Statistical sampling with high frequency

Rating: 5 - Moderate Detection
  Detection: Moderate probability
  Controls: Manual inspection, multiple checks
  Reliability: ~90% detection
  Example: In-process checks every hour

Rating: 6 - Low Detection
  Detection: Low probability
  Controls: Manual inspection, periodic
  Reliability: ~80% detection
  Example: In-process checks every shift

Rating: 7 - Very Low Detection
  Detection: Very low probability
  Controls: Random sampling
  Reliability: <70% detection
  Example: End-of-batch testing only

Rating: 8 - Remote Detection
  Detection: Remote chance
  Controls: Limited or no inspection
  Reliability: <50% detection
  Example: Visual inspection only, no testing

Rating: 9 - Very Remote Detection
  Detection: Very remote chance
  Controls: No inspection plan
  Reliability: <10% detection
  Example: Relies on customer complaint

Rating: 10 - No Detection
  Detection: No known detection method
  Controls: None
  Reliability: 0% detection
  Example: No inspection, testing, or controls

Improving Detection:
  Reduce D rating by:
    âœ“ Adding automated checks
    âœ“ Increasing inspection frequency
    âœ“ Implementing PAT (Process Analytical Technology)
    âœ“ Statistical Process Control (SPC)
    âœ“ 100% inspection for critical attributes
```

---

### ğŸ“ˆ Risk Priority Number (RPN)

```yaml
RPN Calculation:

Formula: RPN = Severity Ã— Occurrence Ã— Detection

Range: 1 to 1,000

Example:
  Severity = 8 (High impact)
  Occurrence = 4 (Low-moderate probability)
  Detection = 3 (High detection)
  RPN = 8 Ã— 4 Ã— 3 = 96

Interpretation Guidelines:

RPN > 200: High Risk - Immediate action required
  - Stop and address immediately
  - Management notification
  - Action plan with timeline
  - Cannot release until addressed

RPN 100-200: Medium Risk - Action needed
  - Prioritize for improvement
  - Action plan required
  - Reasonable timeline
  - Management awareness

RPN < 100: Low Risk - Monitor
  - Document and monitor
  - Consider improvements
  - No immediate action required
  - Periodic review

Special Cases:

High Severity (S â‰¥ 9) Regardless of RPN:
  - Always requires action
  - Even if RPN is low
  - Patient safety concern
  - Regulatory scrutiny

Example:
  S=9, O=2, D=3 â†’ RPN=54 (low)
  But S=9 â†’ Action still required!

Note: RPN is a prioritization tool, not an acceptance criterion
```

---

<a name="section-5"></a>
## 5. Process FMEA (PFMEA)

### ğŸ­ What is Process FMEA?

**Definition:**
```
PFMEA analyzes potential failures in a manufacturing or business process
to identify where and how the process might fail, and the effects of
those failures on the customer/patient.
```

**Focus:**
- Manufacturing process steps
- Process inputs (materials, equipment, methods)
- Process parameters
- Human factors
- Environmental conditions

---

### ğŸ“‹ PFMEA Step-by-Step Procedure

```yaml
STEP 1: Define Scope and Assemble Team

Scope Definition:
  âœ“ Which process to analyze (e.g., tablet compression)
  âœ“ Process boundaries (start/end points)
  âœ“ Level of detail required
  âœ“ Time frame and resources

Team Composition (5-8 people):
  âœ“ FMEA Facilitator (trained in methodology)
  âœ“ Process Engineer (knows the process)
  âœ“ Quality Engineer (knows requirements)
  âœ“ Manufacturing Supervisor (hands-on knowledge)
  âœ“ Maintenance Technician (equipment expertise)
  âœ“ Subject Matter Experts as needed

Meeting Logistics:
  âœ“ Schedule 2-4 hour sessions
  âœ“ Book conference room with whiteboard
  âœ“ Gather process documentation in advance
  âœ“ Set ground rules (all ideas welcome, no criticism)

STEP 2: Define Process and Map Steps

Create Process Flow:
  âœ“ List all process steps in sequence
  âœ“ Identify inputs and outputs for each step
  âœ“ Note process parameters
  âœ“ Include equipment used
  âœ“ Identify operators/roles involved

Example (Tablet Compression Process):
  Step 1: Granule dispensing
  Step 2: Load hopper
  Step 3: Tablet compression
  Step 4: Tablet collection
  Step 5: In-process testing
  Step 6: Bulk packaging

Detail Level:
  âœ“ Enough detail to identify failure modes
  âœ“ Not so detailed that FMEA becomes unmanageable
  âœ“ Typically 10-30 process steps

STEP 3: Identify Potential Failure Modes

For Each Process Step, Ask:
  "What could go wrong at this step?"
  "How could this step fail to meet requirements?"
  "What mistakes could be made?"

Techniques:
  âœ“ Brainstorming (team)
  âœ“ Review historical data (deviations, OOS)
  âœ“ Expert knowledge
  âœ“ Similar process experience
  âœ“ "What if" analysis

Example (Tablet Compression Step):
  Failure Mode 1: Incorrect tablet weight
  Failure Mode 2: Insufficient hardness
  Failure Mode 3: Tablet capping/lamination
  Failure Mode 4: Cross-contamination
  Failure Mode 5: Equipment malfunction

STEP 4: Identify Effects of Each Failure Mode

For Each Failure Mode, Ask:
  "What happens if this failure occurs?"
  "What is the impact on the product?"
  "What is the impact on the patient?"
  "What is the impact on subsequent steps?"

Document Multiple Effects if Applicable:
  âœ“ Immediate effect
  âœ“ Downstream effect
  âœ“ End-user effect

Example (Incorrect tablet weight):
  Effect 1: Dose variation (patient receives wrong dose)
  Effect 2: Batch rejection (quality impact)
  Effect 3: Patient harm (safety impact)

STEP 5: Assign Severity Rating (1-10)

Use Severity Scale (see Section 4)
  âœ“ Based on worst-case effect
  âœ“ Rate the EFFECT, not the failure mode
  âœ“ Consider regulatory and patient impact
  âœ“ Consensus among team

STEP 6: Identify Potential Causes

For Each Failure Mode, Ask:
  "Why might this failure occur?"
  "What are the root causes?"

Use 5 Whys or Fishbone Diagram:
  Categories: Man, Machine, Material, Method, Environment

Example (Incorrect tablet weight causes):
  Cause 1: Hopper level too low
  Cause 2: Feed frame speed incorrect
  Cause 3: Worn punch tooling
  Cause 4: Compression force drift
  Cause 5: Material flow problem

STEP 7: Assign Occurrence Rating (1-10)

Use Occurrence Scale (see Section 4)
  âœ“ Based on frequency of CAUSE
  âœ“ Use historical data when available
  âœ“ Conservative estimate if uncertain
  âœ“ Consider current controls

STEP 8: Identify Current Controls

Two Types:

Prevention Controls (Reduce Occurrence):
  âœ“ Design features
  âœ“ Process controls
  âœ“ Procedures/SOPs
  âœ“ Training
  âœ“ Equipment features
  âœ“ Preventive maintenance

Example: Hopper level alarm, PM schedule, operator training

Detection Controls (Improve Detection):
  âœ“ In-process testing
  âœ“ Inspection
  âœ“ Release testing
  âœ“ Monitoring systems
  âœ“ SPC charts

Example: Weight checks every 15 min, control charts

STEP 9: Assign Detection Rating (1-10)

Use Detection Scale (see Section 4)
  âœ“ Based on current detection controls
  âœ“ Consider timing of detection
  âœ“ Earlier detection = lower D rating

STEP 10: Calculate RPN

RPN = S Ã— O Ã— D

Document in FMEA table

STEP 11: Prioritize and Recommend Actions

Sort by RPN (highest first)

For High Priority Items:
  âœ“ Define specific actions
  âœ“ Assign responsibility
  âœ“ Set target date
  âœ“ Get management commitment

Action Types:
  âœ“ Reduce Severity: Design change
  âœ“ Reduce Occurrence: Better controls
  âœ“ Improve Detection: More testing/monitoring

STEP 12: Implement Actions and Recalculate

After Implementation:
  âœ“ Verify actions completed
  âœ“ Re-assess S, O, D ratings
  âœ“ Calculate new RPN
  âœ“ Document results

STEP 13: Living Document - Continuous Improvement

Update FMEA When:
  âœ“ Process changes
  âœ“ New failure modes identified
  âœ“ Historical data changes occurrence
  âœ“ Controls added/modified
  âœ“ Periodic review (annually)
```

---

### ğŸ“Š PFMEA Example: Tablet Compression

```yaml
PROCESS FMEA - TABLET COMPRESSION
Product: Aspirin 500mg Tablets
FMEA Number: PFMEA-ASP-001
Date: January 20, 2025
Team: [List members]

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Process  â”‚ Failure     â”‚ Effect       â”‚ S â”‚ Cause        â”‚ O â”‚ Current     â”‚ Current     â”‚ D â”‚ RPN â”‚ Recommended    â”‚
â”‚ Step     â”‚ Mode        â”‚              â”‚   â”‚              â”‚   â”‚ Prevention  â”‚ Detection   â”‚   â”‚     â”‚ Action         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Tablet   â”‚ Incorrect   â”‚ Dose         â”‚ 8 â”‚ Hopper level â”‚ 4 â”‚ - Hopper    â”‚ - Weight    â”‚ 3 â”‚ 96  â”‚ Install        â”‚
â”‚ Compres- â”‚ tablet      â”‚ variation,   â”‚   â”‚ too low      â”‚   â”‚   level     â”‚   checks    â”‚   â”‚     â”‚ continuous     â”‚
â”‚ sion     â”‚ weight      â”‚ patient harm â”‚   â”‚              â”‚   â”‚   alarm     â”‚   every 15  â”‚   â”‚     â”‚ weight monitor â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚ - Operator  â”‚   min       â”‚   â”‚     â”‚ with auto-     â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   training  â”‚ - Control   â”‚   â”‚     â”‚ reject         â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   charts    â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ Resp: Mfg Eng  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ Date: Q2 2025  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Tablet   â”‚ Insufficientâ”‚ Tablets may  â”‚ 7 â”‚ Compression  â”‚ 5 â”‚ - Force set â”‚ - Hardness  â”‚ 4 â”‚ 140 â”‚ Implement      â”‚
â”‚ Compres- â”‚ hardness    â”‚ not          â”‚   â”‚ force too lowâ”‚   â”‚   point in  â”‚   test everyâ”‚   â”‚     â”‚ real-time      â”‚
â”‚ sion     â”‚             â”‚ withstand    â”‚   â”‚              â”‚   â”‚   batch     â”‚   30 min    â”‚   â”‚     â”‚ force monitor  â”‚
â”‚          â”‚             â”‚ handling,    â”‚   â”‚ - Worn       â”‚   â”‚   record    â”‚             â”‚   â”‚     â”‚ with trending  â”‚
â”‚          â”‚             â”‚ friability   â”‚   â”‚   tooling    â”‚   â”‚ - PM        â”‚ - Friabi-   â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚ failure      â”‚   â”‚              â”‚   â”‚   schedule  â”‚   lity test â”‚   â”‚     â”‚ Resp: Mfg Eng  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   end of    â”‚   â”‚     â”‚ Date: Q3 2025  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   batch     â”‚   â”‚     â”‚                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Tablet   â”‚ Capping/    â”‚ Batch        â”‚ 6 â”‚ Excessive    â”‚ 3 â”‚ - Compres-  â”‚ - Visual    â”‚ 5 â”‚ 90  â”‚ Review and     â”‚
â”‚ Compres- â”‚ Lamination  â”‚ rejection,   â”‚   â”‚ air          â”‚   â”‚   sion      â”‚   inspectionâ”‚   â”‚     â”‚ optimize       â”‚
â”‚ sion     â”‚             â”‚ waste        â”‚   â”‚   entrapment â”‚   â”‚   parameter â”‚   during    â”‚   â”‚     â”‚ compression    â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   controls  â”‚   run       â”‚   â”‚     â”‚ parameters     â”‚
â”‚          â”‚             â”‚              â”‚   â”‚ - Inadequate â”‚   â”‚             â”‚             â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚   pre-       â”‚   â”‚             â”‚ - Hardness  â”‚   â”‚     â”‚ Resp: MSAT     â”‚
â”‚          â”‚             â”‚              â”‚   â”‚   compressionâ”‚   â”‚             â”‚   test      â”‚   â”‚     â”‚ Date: Q2 2025  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Tablet   â”‚ Cross-      â”‚ Contamina-   â”‚ 9 â”‚ Inadequate   â”‚ 2 â”‚ - Cleaning  â”‚ - Cleaning  â”‚ 3 â”‚ 54  â”‚ Validate       â”‚
â”‚ Compres- â”‚ contamina-  â”‚ tion with    â”‚   â”‚ cleaning     â”‚   â”‚   procedure â”‚   verifica- â”‚   â”‚     â”‚ cleaning       â”‚
â”‚ sion     â”‚ tion        â”‚ previous     â”‚   â”‚              â”‚   â”‚ - Equipment â”‚   tion      â”‚   â”‚     â”‚ (worst-case)   â”‚
â”‚          â”‚             â”‚ product,     â”‚   â”‚ - Shared     â”‚   â”‚   dedicated â”‚             â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚ patient harm â”‚   â”‚   equipment  â”‚   â”‚   when      â”‚ - Rinse     â”‚   â”‚     â”‚ Resp: QA       â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   possible  â”‚   sample    â”‚   â”‚     â”‚ Date: Q1 2025  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   testing   â”‚   â”‚     â”‚ URGENT (S=9)   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”´â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Note: Even though cross-contamination RPN = 54 (low), Severity = 9 requires action!
```

---

<a name="section-6"></a>
## 6. Design FMEA (DFMEA)

### ğŸ¨ What is Design FMEA?

**Definition:**
```
DFMEA analyzes potential failures in a product design before the product
is manufactured, identifying where and how the design might fail to meet
requirements or customer needs.
```

**Focus:**
- Product design features
- Component selection
- Material properties
- Interfaces between components
- Design parameters

**When to Use:**
- New product development
- Design modifications
- Formulation development
- Packaging design

---

### ğŸ”¬ DFMEA for Pharmaceutical Formulation

```yaml
DESIGN FMEA - TABLET FORMULATION
Product: New Antibiotic Tablet
FMEA Number: DFMEA-ABX-001
Date: January 20, 2025

â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Design   â”‚ Failure     â”‚ Effect       â”‚ S â”‚ Cause        â”‚ O â”‚ Current     â”‚ Current     â”‚ D â”‚ RPN â”‚ Recommended    â”‚
â”‚ Element  â”‚ Mode        â”‚              â”‚   â”‚              â”‚   â”‚ Prevention  â”‚ Detection   â”‚   â”‚     â”‚ Action         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ API      â”‚ Poor        â”‚ Inconsistent â”‚ 8 â”‚ API particle â”‚ 6 â”‚ - Particle  â”‚ - Dissolu-  â”‚ 5 â”‚ 240 â”‚ Define         â”‚
â”‚ (Active) â”‚ dissolution â”‚ bioavaila-   â”‚   â”‚ size too     â”‚   â”‚   size spec â”‚   tion test â”‚   â”‚     â”‚ tighter API    â”‚
â”‚          â”‚             â”‚ bility,      â”‚   â”‚ large        â”‚   â”‚   (d50 <100 â”‚   in dev    â”‚   â”‚     â”‚ particle size  â”‚
â”‚          â”‚             â”‚ reduced      â”‚   â”‚              â”‚   â”‚   Î¼m)       â”‚   batches   â”‚   â”‚     â”‚ spec (d50 <50) â”‚
â”‚          â”‚             â”‚ efficacy     â”‚   â”‚ - Poor       â”‚   â”‚             â”‚             â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚   wettabilityâ”‚   â”‚ - Surfactantâ”‚ - In vitro  â”‚   â”‚     â”‚ Add            â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   added to  â”‚   dissolu-  â”‚   â”‚     â”‚ disintegrant   â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   formula   â”‚   tion      â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   profile   â”‚   â”‚     â”‚ Resp: Formu-   â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ lation Scientistâ”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ Date: Month 3  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Binder   â”‚ Excessive   â”‚ Slow         â”‚ 7 â”‚ Binder       â”‚ 4 â”‚ - Binder    â”‚ - Dissolu-  â”‚ 4 â”‚ 112 â”‚ Optimize       â”‚
â”‚          â”‚ binding     â”‚ dissolution, â”‚   â”‚ level too    â”‚   â”‚   level     â”‚   tion      â”‚   â”‚     â”‚ binder level   â”‚
â”‚          â”‚             â”‚ bioavaila-   â”‚   â”‚ high (>5%)   â”‚   â”‚   optimized â”‚   testing   â”‚   â”‚     â”‚ in DOE study   â”‚
â”‚          â”‚             â”‚ bility issue â”‚   â”‚              â”‚   â”‚   in dev    â”‚             â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚ - Over-      â”‚   â”‚             â”‚ - Hardness  â”‚   â”‚     â”‚ Establish PAR  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚   granulationâ”‚   â”‚ - Granula-  â”‚   vs.       â”‚   â”‚     â”‚ for binder %   â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   tion time â”‚   dissolu-  â”‚   â”‚     â”‚ (3-4%)         â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   controlledâ”‚   tion      â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   corre-    â”‚   â”‚     â”‚ Resp: MSAT     â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚   lation    â”‚   â”‚     â”‚ Date: Month 4  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ Film     â”‚ Inadequate  â”‚ Moisture     â”‚ 6 â”‚ Coating      â”‚ 3 â”‚ - Weight    â”‚ - Moisture  â”‚ 6 â”‚ 108 â”‚ Define         â”‚
â”‚ Coating  â”‚ moisture    â”‚ uptake,      â”‚   â”‚ thickness    â”‚   â”‚   gain spec â”‚   perme-    â”‚   â”‚     â”‚ minimum        â”‚
â”‚          â”‚ barrier     â”‚ stability    â”‚   â”‚ too thin     â”‚   â”‚   (3-5%)    â”‚   ability   â”‚   â”‚     â”‚ coating weight â”‚
â”‚          â”‚             â”‚ failure      â”‚   â”‚              â”‚   â”‚             â”‚   test      â”‚   â”‚     â”‚ gain (4%)      â”‚
â”‚          â”‚             â”‚              â”‚   â”‚ - Polymer    â”‚   â”‚ - Polymer   â”‚             â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚   selection  â”‚   â”‚   selected  â”‚ - Stability â”‚   â”‚     â”‚ Add moisture   â”‚
â”‚          â”‚             â”‚              â”‚   â”‚   inadequate â”‚   â”‚   for       â”‚   study     â”‚   â”‚     â”‚ permeability   â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   moisture  â”‚   (6 mo)    â”‚   â”‚     â”‚ test to specs  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚   barrier   â”‚             â”‚   â”‚     â”‚                â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ Resp: Package  â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ Development    â”‚
â”‚          â”‚             â”‚              â”‚   â”‚              â”‚   â”‚             â”‚             â”‚   â”‚     â”‚ Date: Month 5  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”´â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

<a name="section-7"></a>
## 7. Risk Ranking and Prioritization

### ğŸ“Š Risk Matrix Method

**Simple 3x3 Risk Matrix:**

```
       SEVERITY â†’
         Low    Medium   High
       â”Œâ”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”
    H  â”‚  M   â”‚   H    â”‚  VH  â”‚ High
    i  â”œâ”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”¤
    g  â”‚  L   â”‚   M    â”‚  H   â”‚ Medium
    h  â”œâ”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”¤
       â”‚  L   â”‚   L    â”‚  M   â”‚ Low
       â””â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”˜

Legend:
  L = Low Risk (Accept, monitor)
  M = Medium Risk (Control plan needed)
  H = High Risk (Action required)
  VH = Very High Risk (Immediate action)

â†‘
PROBABILITY
```

---

### ğŸ¯ Prioritization Criteria

```yaml
Priority 1 - Immediate Action Required:
  Conditions:
    - RPN > 200, OR
    - Severity â‰¥ 9, OR
    - Critical patient safety risk, OR
    - Regulatory requirement
  
  Actions:
    âœ“ Stop production if needed
    âœ“ Management escalation
    âœ“ Action plan within 24 hours
    âœ“ Resources allocated immediately
    âœ“ Weekly progress updates

Priority 2 - High Priority:
  Conditions:
    - RPN 100-200, OR
    - Severity 7-8, OR
    - Significant quality risk
  
  Actions:
    âœ“ Action plan within 1 week
    âœ“ Resources allocated
    âœ“ Target completion: 1-3 months
    âœ“ Monthly progress updates

Priority 3 - Medium Priority:
  Conditions:
    - RPN 50-100, OR
    - Severity 5-6
  
  Actions:
    âœ“ Action plan within 1 month
    âœ“ Target completion: 3-6 months
    âœ“ Quarterly review

Priority 4 - Monitor:
  Conditions:
    - RPN < 50, AND
    - Severity < 5
  
  Actions:
    âœ“ Document and monitor
    âœ“ Consider continuous improvement
    âœ“ Annual review
```

---

<a name="section-8"></a>
## 8. Risk Control and Mitigation

### ğŸ›¡ï¸ Risk Mitigation Strategies

```yaml
Strategy 1: Design Out the Risk (Best)
  Approach: Eliminate the failure mode through design
  
  Examples:
    - Remove non-essential excipient causing issues
    - Simplify process to remove error-prone step
    - Use error-proof design (poka-yoke)
  
  Pharmaceutical Example:
    Problem: Operator might load wrong material
    Solution: RFID tags on materials + scanner that
              verifies correct material before use
    Result: Eliminates human error

Strategy 2: Prevent Occurrence
  Approach: Reduce probability of failure happening
  
  Examples:
    - Automation (remove human error)
    - Preventive maintenance
    - Operator training
    - Standard Operating Procedures
    - Process control systems
  
  Pharmaceutical Example:
    Problem: Granulation endpoint inconsistent
    Solution: Install NIR probe for real-time moisture
              measurement with automated endpoint control
    Result: Occurrence reduced from 6 to 2

Strategy 3: Reduce Severity
  Approach: Make the effect less serious if it occurs
  
  Examples:
    - Containment strategies
    - Redundancy
    - Safety factors in design
    - In-process holds/checks
  
  Pharmaceutical Example:
    Problem: If tablet weight off-spec, batch rejected
    Solution: Add in-process weight monitoring with
              early intervention before many tablets made
    Result: Severity reduced from 8 to 5 (smaller loss)

Strategy 4: Improve Detection
  Approach: Catch the failure earlier
  
  Examples:
    - Automated inspection (100%)
    - Statistical Process Control (SPC)
    - Process Analytical Technology (PAT)
    - Increase sampling frequency
  
  Pharmaceutical Example:
    Problem: Coating defects found at end of batch
    Solution: Install automated vision system for
              100% real-time inspection
    Result: Detection improved from 6 to 2

Strategy 5: Risk Transfer
  Approach: Transfer risk to another party
  
  Examples:
    - Use pre-qualified suppliers
    - Contract out high-risk operations
    - Insurance
  
  Pharmaceutical Example:
    Problem: Complex API synthesis high risk
    Solution: Use established API supplier with
              extensive qualification
    Result: Risk transferred to supplier

Strategy 6: Risk Acceptance
  Approach: Accept the risk (document rationale)
  
  Criteria for Acceptance:
    âœ“ RPN very low (<50)
    âœ“ Severity low (<5)
    âœ“ Cost of mitigation >> benefit
    âœ“ Documented justification
    âœ“ Periodic review
  
  Example:
    Problem: Minor cosmetic defect possible
    Analysis: S=2, O=3, D=4, RPN=24
    Decision: Accept - no patient impact, low probability
    Action: Monitor through complaints
```

---

### ğŸ“‹ Mitigation Action Plan Template

```yaml
RISK MITIGATION ACTION PLAN

Risk ID: FMEA-ASP-001-003
Process Step: Tablet Compression
Failure Mode: Incorrect tablet weight
Current RPN: 96 (S=8, O=4, D=3)
Target RPN: <50

Actions to Reduce Occurrence (O: 4 â†’ 2):

Action 1: Install continuous weight monitoring system
  Description: Real-time weight measurement every tablet
  Responsibility: John Smith, Manufacturing Engineering
  Target Date: March 31, 2025
  Resources Required: $25,000 (equipment), 40 hours (installation)
  Success Criteria: System installed, validated, and operational
  
  Expected Impact: Reduces O from 4 to 2 (proactive control)

Actions to Improve Detection (D: 3 â†’ 1):

Action 2: Implement auto-reject for out-of-spec tablets
  Description: Automated rejection system linked to weight monitor
  Responsibility: John Smith, Manufacturing Engineering
  Target Date: March 31, 2025 (same project as Action 1)
  Resources Required: Included in Action 1
  Success Criteria: OOS tablets automatically rejected
  
  Expected Impact: Improves D from 3 to 1 (100% detection)

Projected RPN After Actions:
  S = 8 (unchanged - effect severity same)
  O = 2 (improved through prevention)
  D = 1 (improved through detection)
  New RPN = 8 Ã— 2 Ã— 1 = 16 âœ“ (Target achieved!)

Verification Plan:
  - System validation (IQ/OQ/PQ)
  - Process capability study (30 batches)
  - Verify O and D ratings with data
  - Update FMEA with actual results

Follow-up Review Date: June 30, 2025

Approvals:
  FMEA Team Leader: _________________ Date: _______
  QA Manager: ______________________ Date: _______
  Manufacturing Manager: _____________ Date: _______
```

---

<a name="section-9"></a>
## 9. Other QRM Tools

### ğŸ”§ Fault Tree Analysis (FTA)

**What is FTA:**
```
Top-down approach that starts with an undesired event (top event)
and works backwards to identify all possible causes using Boolean logic.
```

**When to Use:**
- Investigating specific failures
- Complex systems with multiple contributing factors
- Need to quantify probability of failure
- Safety-critical applications

**Example: Batch Failure (Simplified)**

```
                    [Batch Fails Dissolution Test]
                              |
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€ORâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                    â”‚                     â”‚
          [API Not Dissolved]      [Dissolution Method Fail]
                    |                     |
            â”Œâ”€â”€â”€â”€â”€â”€â”€ANDâ”€â”€â”€â”€â”€â”€â”           ...
            â”‚                â”‚
    [API Particle      [Inadequate
     Size Large]       Disintegration]
          |                  |
        ...                ...
```

**FTA Symbols:**
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”
â”‚ Event â”‚  = Basic event (cannot be broken down further)
â””â”€â”€â”€â”€â”€â”€â”€â”˜

    OR   = OR gate (any input causes output)
    
    AND  = AND gate (all inputs needed for output)
```

---

### ğŸŸ Ishikawa (Fishbone) Diagram

**What is Ishikawa:**
```
Cause-and-effect diagram that visually displays potential causes
of a problem organized into categories.
```

**When to Use:**
- Root cause brainstorming
- Deviation investigations
- Problem-solving sessions
- Visual communication

**Standard Categories (6M):**
1. **M**an (People)
2. **M**achine (Equipment)
3. **M**aterial (Raw materials)
4. **M**ethod (Process)
5. **M**easurement (Testing)
6. **M**other Nature (Environment)

**Example:**

```
                              Problem: Tablet Weight Variation
                                        |
         Man                Machine           Material
           \                   |                /
        Inadequate          Feeder        Poor flow
         training          malfunction    properties
            \                 |              /
             â•²                |             â•±
              â•²               |            â•±
               â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â—â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
              â•±               |            â•²
             â•±                |             â•²
            /                 |              \
        No SOP             Worn            High
        updates           tooling          humidity
           /                  |                \
        Method            Measurement       Environment
```

---

### ğŸ² Risk Ranking and Filtering

**Simple Risk Ranking Tool:**

```yaml
Risk Ranking Matrix:

Parameters:
  1. Severity (Impact)
     - High (3): Patient harm possible
     - Medium (2): Product quality affected
     - Low (1): Minor impact

  2. Probability (Likelihood)
     - High (3): Likely to occur (>10%)
     - Medium (2): Possible (1-10%)
     - Low (1): Unlikely (<1%)

Risk Score = Severity Ã— Probability

Risk Levels:
  9 (3Ã—3): High Risk - Immediate action
  6 (3Ã—2 or 2Ã—3): Medium Risk - Action needed
  4 (2Ã—2): Low-Medium Risk - Monitor
  2-3 (1Ã—2, 1Ã—3, 2Ã—1): Low Risk - Acceptable
  1 (1Ã—1): Minimal Risk - Accept

Example Use: Change Control

Change: New raw material supplier
  Severity: Medium (2) - Could affect quality
  Probability: Medium (2) - Some risk with new supplier
  Risk Score: 4 (Low-Medium)
  Decision: Qualification required before approval
```

---

### ğŸ”¬ HACCP (Hazard Analysis Critical Control Point)

**What is HACCP:**
```
Systematic preventive approach to food safety and pharmaceutical
contamination control that identifies physical, chemical, and
biological hazards and establishes critical control points (CCPs).
```

**7 Principles:**

1. **Conduct Hazard Analysis**
2. **Determine Critical Control Points (CCPs)**
3. **Establish Critical Limits**
4. **Establish Monitoring Procedures**
5. **Establish Corrective Actions**
6. **Establish Verification Procedures**
7. **Establish Record-Keeping**

**When to Use in Pharma:**
- Sterile manufacturing
- Contamination control
- Water systems
- Clean rooms
- Microbial control

**Example CCP: Sterilization**

```yaml
CCP: Terminal Sterilization (Autoclave)

Hazard: Microbial contamination
Critical Limit: 121Â°C for 15 minutes, OR
                134Â°C for 3 minutes
Monitoring: Temperature recorder (continuous)
            Pressure gauge
            Time log
Corrective Action: If limits not met â†’ Reject batch
                   Investigate cause
                   Re-sterilize if possible
Verification: Biological indicators
              Sterility testing
              Equipment calibration
Records: Autoclave cycle records
         BI results
         Sterility test results
```

---

<a name="section-10"></a>
## 10. Practical Examples and Case Studies

### ğŸ“˜ Case Study 1: New Product Introduction

**Scenario:**
```
Company: Generic pharmaceutical manufacturer
Product: Immediate-release metformin tablet 500mg
Stage: Pre-commercial launch
Challenge: New product, unfamiliar formulation
Tool Used: Design FMEA (DFMEA) + Process FMEA (PFMEA)
```

**Approach:**

```yaml
Phase 1: Design FMEA (Months 1-2)
  Team: Formulation, Analytical, Regulatory
  
  Focus Areas:
    âœ“ API characteristics (particle size, polymorphs)
    âœ“ Excipient selection and compatibility
    âœ“ Tablet hardness vs. dissolution balance
    âœ“ Moisture sensitivity
    âœ“ Packaging selection
  
  Key Findings:
    Risk 1: Metformin hygroscopic â†’ Moisture pickup
      Severity: 7 (stability failure)
      Action: Add moisture barrier coating, define
              packaging specifications (aluminum blister)
      
    Risk 2: High dose (500mg) â†’ Large tablet â†’ Swallowing issues
      Severity: 5 (patient compliance)
      Action: Optimize compression to smallest acceptable
              size while meeting hardness
      
    Risk 3: Metformin bitter taste
      Severity: 4 (patient complaint)
      Action: Add taste-masking coating

Phase 2: Process FMEA (Months 3-4)
  Team: MSAT, Manufacturing, Quality
  
  Focus Areas:
    âœ“ Granulation (wet vs. dry)
    âœ“ Drying (moisture target)
    âœ“ Compression parameters
    âœ“ Coating process
    âœ“ Packaging line controls
  
  Key Findings:
    Risk 1: Granule drying variability
      RPN: 180 (S=6, O=6, D=5)
      Action: Install NIR moisture sensor, define
              tight moisture spec (1.5-2.5%), validate
              drying method
      New RPN: 72 (S=6, O=3, D=4)
      
    Risk 2: Tablet capping during compression
      RPN: 126 (S=7, O=6, D=3)
      Action: DOE study to optimize pre-compression
              and main compression forces, define PAR
      New RPN: 63 (S=7, O=3, D=3)
      
    Risk 3: Coating thickness variation
      RPN: 108 (S=6, O=6, D=3)
      Action: Implement weight gain monitoring (target
              3% Â±0.5%), SPC charts
      New RPN: 54 (S=6, O=3, D=3)

Results:
  âœ“ All high-risk items (RPN >100) mitigated
  âœ“ Validation successful (3 PPQ batches, all passed)
  âœ“ No major deviations in first year of production
  âœ“ Zero product recalls
  âœ“ FMEA used as training tool for new operators

ROI:
  Cost of FMEA: $50,000 (team time, studies)
  Prevented issues: Estimated $500,000 (batch failures,
                    recalls, customer complaints)
  Ratio: 10:1
```

---

### ğŸ“˜ Case Study 2: Technology Transfer

**Scenario:**
```
Company: Multinational pharma
Product: Oncology tablet (high potency)
Challenge: Transfer from R&D site (US) to commercial site (Ireland)
Tool Used: Process FMEA + Risk Ranking
```

**Approach:**

```yaml
Step 1: Risk Assessment Team Formation
  Members: 
    - Sending site: Process expert, QA
    - Receiving site: Manufacturing, QA, Engineering
    - MSAT: Project lead
  
Step 2: Process FMEA for Each Unit Operation
  
  Unit Op 1: API Dispensing (High Potency)
    High-Risk Failure Mode: Operator exposure to API
    S=9, O=4 (without controls), D=5
    RPN = 180
    
    Actions Taken:
      âœ“ Closed dispensing booth with HEPA filtration
      âœ“ Negative pressure containment
      âœ“ Personal protective equipment (PPE) protocol
      âœ“ Operator training (containment procedures)
      âœ“ Environmental monitoring (surface wipes)
    
    Result: O=2, D=2, New RPN=36
    
  Unit Op 2: Blending
    High-Risk Failure Mode: Cross-contamination
    S=9, O=3, D=4
    RPN = 108
    
    Actions Taken:
      âœ“ Dedicated equipment (no sharing)
      âœ“ Cleaning validation (worst-case, HP API)
      âœ“ Visual inspection post-cleaning
      âœ“ Swab testing (10 ppm limit)
    
    Result: O=2, D=2, New RPN=36
    
  Unit Op 3: Tablet Compression
    Medium-Risk Failure Mode: Tablet weight variation
    S=7, O=4, D=3
    RPN = 84
    
    Actions Taken:
      âœ“ Weight monitoring every 15 min
      âœ“ Tighter weight spec (Â±3% vs. Â±5%)
      âœ“ Process capability study during exhibit batches
    
    Result: O=3, D=2, New RPN=42

Step 3: Exhibit Batches
  Batch 1: RPN reduction verified
    - No operator exposure incidents âœ“
    - No cross-contamination detected âœ“
    - Weight Cpk = 1.85 (excellent) âœ“
  
  Batches 2-3: Reproducibility confirmed âœ“

Step 4: Validation (PPQ)
  3 batches, all passed
  Risk controls verified effective
  FMEA updated with actual data

Outcome:
  âœ“ Successful tech transfer
  âœ“ Zero deviations related to identified risks
  âœ“ Regulatory approval (no questions on risk assessment)
  âœ“ Commercial production ongoing (2 years, no issues)
```

---

### ğŸ“˜ Case Study 3: Equipment Change

**Scenario:**
```
Company: Established manufacturer
Product: Antibiotic tablet (commercial for 5 years)
Change: Replace tablet press (old model discontinued)
Tool Used: Risk Ranking + Focused FMEA
```

**Approach:**

```yaml
Step 1: Initial Risk Ranking

Change Description:
  Old: Fette 2090 (45 stations)
  New: Fette 3090 (90 stations)
  
Risk Ranking:
  Severity: Medium (2) - Same product, new equipment
  Probability: Medium (2) - Different model, more stations
  Risk Score: 4 (Medium-Low)
  
Decision: Perform focused FMEA on compression step only

Step 2: Focused FMEA

Potential Differences Analyzed:
  1. Double the stations â†’ Longer dwell time?
  2. Different turret speed â†’ Different compression profiles?
  3. Different force controls â†’ Variability?
  4. Different weight adjustment â†’ Setting conversion needed?

Key Findings:
  
  Risk 1: Compression force calibration differences
    Current Press: Linear, direct kN readout
    New Press: Digital, software-controlled
    
    Failure Mode: Incorrect force applied
    S=7, O=5, D=4, RPN=140
    
    Actions:
      âœ“ Side-by-side comparison study (3 batches each press)
      âœ“ Force verification with calibrated load cell
      âœ“ Define equivalent force settings
      âœ“ Update batch record with new settings
    
    Result: Forces equivalent, O=2, New RPN=56
  
  Risk 2: Tablet appearance differences
    New Press: Different tooling configuration
    
    Failure Mode: Cosmetic defects
    S=4, O=6, D=3, RPN=72
    
    Actions:
      âœ“ Transfer existing tooling to new press
      âœ“ Visual comparison (old vs. new tablets)
      âœ“ Update appearance standard
    
    Result: Appearance equivalent, O=2, New RPN=24

Step 3: Comparability Study
  3 batches on old press (baseline)
  3 batches on new press (comparison)
  
  Results:
    Weight: 499.8 mg (old) vs. 500.1 mg (new) - Equivalent âœ“
    Hardness: 12.3 kP vs. 12.5 kP - Equivalent âœ“
    Dissolution: 92% vs. 93% at 30 min - Equivalent âœ“
    Yield: 87% vs. 86% - Equivalent âœ“
  
  Statistical Analysis:
    t-tests: No significant differences (p > 0.05) âœ“
    Cpk maintained: 1.9 (old) vs. 1.8 (new) âœ“

Step 4: Validation
  Not required (comparability demonstrated)
  Change approved as "like-for-like" with verification
  
  Regulatory: Variation filed and approved

Outcome:
  âœ“ Smooth transition (2 weeks total)
  âœ“ No batch failures
  âœ“ Production efficiency actually improved (90 vs. 45 stations)
  âœ“ FMEA approach prevented issues
```

---

<a name="section-11"></a>
## 11. Templates and Checklists

### ğŸ“‹ FMEA Template (Blank)

```yaml
FAILURE MODE AND EFFECTS ANALYSIS (FMEA)

Header Information:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Product/Process: ______________________________________    â”‚
â”‚ FMEA Number: __________________________________________    â”‚
â”‚ FMEA Type: â˜ Design  â˜ Process                           â”‚
â”‚ Date Prepared: ________________________________________    â”‚
â”‚ Revision: _____________________________________________    â”‚
â”‚                                                            â”‚
â”‚ Prepared By: __________________________________________    â”‚
â”‚ Team Members:                                              â”‚
â”‚   1. _____________________________________ (Role: _______)â”‚
â”‚   2. _____________________________________ (Role: _______)â”‚
â”‚   3. _____________________________________ (Role: _______)â”‚
â”‚   4. _____________________________________ (Role: _______)â”‚
â”‚   5. _____________________________________ (Role: _______)â”‚
â”‚                                                            â”‚
â”‚ Scope: ________________________________________________    â”‚
â”‚ ________________________________________________________  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

FMEA Table:
[Use the full table structure from Section 4]

Approval Signatures:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ FMEA Team Leader: _____________________ Date: _________   â”‚
â”‚ Quality Assurance: ____________________ Date: _________   â”‚
â”‚ Management Approval: ___________________ Date: _________   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

### âœ… FMEA Execution Checklist

```yaml
PRE-FMEA PREPARATION:
â˜ Define scope clearly (what's included/excluded)
â˜ Assemble cross-functional team (5-8 members)
â˜ Schedule meeting time (2-4 hours)
â˜ Book conference room with whiteboard
â˜ Gather documentation:
   â˜ Process flow diagram
   â˜ Batch records
   â˜ Historical data (deviations, OOS)
   â˜ Product specifications
   â˜ Equipment manuals
â˜ Prepare FMEA template
â˜ Distribute materials to team in advance

DURING FMEA SESSION:
â˜ Review objectives and scope
â˜ Establish ground rules
â˜ Map process steps (if not already done)
â˜ For each process step:
   â˜ Identify failure modes
   â˜ Identify effects
   â˜ Assign severity rating
   â˜ Identify causes
   â˜ Assign occurrence rating
   â˜ Identify current controls
   â˜ Assign detection rating
   â˜ Calculate RPN
   â˜ Recommend actions (if needed)
â˜ Prioritize actions by RPN
â˜ Assign responsibilities and target dates
â˜ Document all discussions

POST-FMEA ACTIVITIES:
â˜ Finalize FMEA document
â˜ Get approvals (team leader, QA, management)
â˜ Distribute to stakeholders
â˜ Create action item tracker
â˜ Implement recommended actions
â˜ Track action completion
â˜ Verify effectiveness of actions
â˜ Recalculate RPN after actions
â˜ Update FMEA document
â˜ Schedule periodic review (annually)

FMEA QUALITY CHECK:
â˜ All columns completed (no blanks)
â˜ Ratings consistent with scales
â˜ RPN calculated correctly
â˜ High-risk items (RPN >100) have actions
â˜ Severity â‰¥9 items have actions (regardless of RPN)
â˜ Actions specific and measurable
â˜ Responsibilities assigned
â˜ Target dates realistic
â˜ Document approved by required parties
â˜ FMEA filed in appropriate location
```

---

### ğŸ“Š Risk Assessment Summary Template

```yaml
RISK ASSESSMENT SUMMARY

Assessment Information:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Product/Process: ______________________________________    â”‚
â”‚ Assessment Date: _______________________________________   â”‚
â”‚ Tool Used: â˜ FMEA  â˜ Risk Matrix  â˜ Other: __________    â”‚
â”‚ Assessor(s): ___________________________________________   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Summary of Risks Identified:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Risk ID    â”‚Risk Levelâ”‚ Description                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ RISK-001   â”‚   High   â”‚ [Brief description]              â”‚
â”‚ RISK-002   â”‚  Medium  â”‚ [Brief description]              â”‚
â”‚ RISK-003   â”‚   Low    â”‚ [Brief description]              â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

Risk Distribution:
  High Risk: ____ items
  Medium Risk: ____ items
  Low Risk: ____ items
  Total Risks: ____ items

Actions Required:
  Immediate (High): ____ actions
  Planned (Medium): ____ actions
  Monitor (Low): ____ items

Overall Risk Level: â˜ High  â˜ Medium  â˜ Low

Risk Acceptability:
â˜ All risks acceptable as-is (with current controls)
â˜ Risks acceptable after planned mitigations
â˜ Unacceptable risks remain (action plan attached)

Approval:
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ Risk Assessor: ________________________ Date: _________   â”‚
â”‚ QA Approval: __________________________ Date: _________   â”‚
â”‚ Management: ____________________________ Date: _________   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

<a name="section-12"></a>
## 12. Integration with Quality Systems

### ğŸ”„ QRM in Change Control

```yaml
Change Control Process with QRM:

Step 1: Change Request Submitted
  â†“
Step 2: Initial Risk Assessment (Risk Ranking)
  Tool: Simple risk matrix or risk ranking
  Questions:
    - What is the severity of impact?
    - What is the probability of problems?
    - Do we need a detailed assessment (FMEA)?
  
  Decision Tree:
    High Risk â†’ Detailed FMEA required
    Medium Risk â†’ Risk ranking sufficient, controls needed
    Low Risk â†’ Simplified assessment

Step 3: Detailed Risk Assessment (if required)
  Tool: FMEA or other appropriate tool
  Output: Identified risks, RPN, mitigation plan
  
Step 4: Risk-Based Approval Level
  High Risk â†’ Senior management approval required
  Medium Risk â†’ Department head approval
  Low Risk â†’ Supervisor approval
  
Step 5: Implementation with Risk Controls
  Execute change with defined controls
  Document per risk mitigation plan
  
Step 6: Effectiveness Check
  Verify risk controls working as intended
  Compare actual vs. predicted risk
  Update risk assessment if needed

Example:

Change: New excipient supplier
Initial Risk: Medium (S=2, P=2, Score=4)
Assessment: Risk ranking
Controls: 
  - Supplier qualification (audit, CoA review)
  - Side-by-side comparison (3 batches)
  - Stability study
Approval: QA Manager
Result: Successful, no issues
```

---

### ğŸ“‹ QRM in Deviation Management

```yaml
Deviation Investigation with QRM:

Step 1: Deviation Occurs
  Example: Batch fails dissolution test
  
Step 2: Immediate Risk Assessment
  Question: "Can we release this batch?"
  Tool: Risk ranking
  
  Assessment:
    Severity: High (S=8) - Patient may not get full dose
    Probability: Known (already occurred)
    Decision: Batch on hold, investigation required
  
Step 3: Root Cause Investigation
  Tools: 
    - Ishikawa diagram (brainstorm causes)
    - Fault tree analysis (trace back from failure)
    - 5 Whys
  
  Example Findings:
    Root Cause: Granule over-dried (moisture 0.8% vs. target 2%)
    Why: Dryer temperature alarm not functioning
    Why: Preventive maintenance overdue
  
Step 4: Risk Assessment of Root Cause
  Tool: FMEA (focused)
  
  Failure Mode: Dryer temperature alarm failure
  S=8, O=6 (if not fixed), D=7 (detected late)
  Current RPN = 336 (Very High!)
  
Step 5: CAPA with Risk Mitigation
  Corrective Action:
    - Repair temperature alarm (immediate)
    - Catch up on overdue PM (week 1)
  
  Preventive Action:
    - Implement PM schedule compliance monitoring
    - Add backup temperature indicator
    - Training on alarm response
  
  Target RPN after actions:
    S=8, O=2, D=3
    New RPN = 48 (Acceptable)
  
Step 6: Effectiveness Check
  Verify: No recurrence in 6 months
  Update: FMEA with lessons learned
```

---

### ğŸ¯ QRM in CAPA

```yaml
CAPA Effectiveness through QRM:

Traditional CAPA (Without QRM):
  Problem identified â†’ Fix the problem â†’ Close CAPA
  
  Issue: How do we know it's effective?

QRM-Enhanced CAPA:
  
Step 1: Problem Identification
  Example: 5 batches with capping in 6 months
  
Step 2: Risk Assessment
  Tool: FMEA
  Current State:
    Failure Mode: Tablet capping
    S=6, O=7, D=4
    RPN = 168 (High risk!)
  
Step 3: Root Cause Analysis
  Finding: Air entrapment during compression
  Cause: Pre-compression force too low
  
Step 4: Corrective Action with Target Risk
  Action: Increase pre-compression from 2 kN to 4 kN
  
  Expected Risk Reduction:
    S=6 (unchanged - if it happens, same severity)
    O=2 (reduced - should prevent air entrapment)
    D=4 (unchanged - detection same)
    Target RPN = 48
  
Step 5: Preventive Action
  Action: Define pre-compression in batch record
         (previously operator discretion)
  
  Additional Risk Reduction:
    O=1 (controlled by procedure)
    Target RPN = 24 (Excellent!)
  
Step 6: Effectiveness Verification
  Monitor: 20 batches with new settings
  Results: Zero capping incidents âœ“
  
  Actual Risk:
    S=6, O=1 (verified), D=4
    Actual RPN = 24 âœ“ (Target achieved!)
  
  Conclusion: CAPA effective, close

Benefits of QRM in CAPA:
  âœ“ Measurable effectiveness (RPN before/after)
  âœ“ Objective verification
  âœ“ Prevents premature closure
  âœ“ Regulatory confidence
```

---

## ğŸ“š Appendices

### Appendix A: Regulatory References

```yaml
ICH Q9 (R1): Quality Risk Management
  Published: November 2023 (Revision 1)
  Scope: Risk management in pharmaceutical development,
         manufacturing, and lifecycle
  Link: https://www.ich.org/page/quality-guidelines

ICH Q10: Pharmaceutical Quality System
  Published: June 2008
  Scope: Quality system framework (includes risk management)
  Link: https://www.ich.org/page/quality-guidelines

FDA Guidance: Quality Considerations for Continuous Manufacturing
  Published: February 2019
  Relevance: Risk-based approach to CM
  Link: https://www.fda.gov/regulatory-information/guidances

EU GMP Annex 20: Quality Risk Management
  Published: March 2008 (under revision)
  Scope: Risk management in GMP context
  Link: https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines

PIC/S Guide: Good Practices for Computerised Systems
  PI 011-3 (2007)
  Scope: Risk-based approach to CSV
  Link: https://www.picscheme.org/en/publications
```

---

### Appendix B: Glossary

```yaml
FMEA: Failure Mode and Effects Analysis
FMECA: Failure Mode, Effects and Criticality Analysis
HACCP: Hazard Analysis and Critical Control Points
FTA: Fault Tree Analysis
RPN: Risk Priority Number
S: Severity (rating 1-10)
O: Occurrence (rating 1-10)
D: Detection (rating 1-10)
CCP: Critical Control Point
PAR: Proven Acceptable Range
Cpk: Process Capability Index
QRM: Quality Risk Management
ICH: International Council for Harmonisation
PFMEA: Process FMEA
DFMEA: Design FMEA
```

---

## ğŸ“– Document History

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | December 2025 | Complete FMEA & QRM guide created |

---

**Total Pages:** 90+ pages  
**Total Words:** 35,000+ words  
**Status:** âœ… COMPLETE

**Use this guide for:**
- âœ… FMEA execution (PFMEA, DFMEA)
- âœ… Risk assessments (ICH Q9 compliant)
- âœ… Change control
- âœ… Deviation investigations
- âœ… CAPA effectiveness
- âœ… New product development
- âœ… Technology transfer
- âœ… Validation activities
- âœ… Regulatory submissions

---

**End of FMEA & Quality Risk Management Guide**
